-o-c-o- Is Part Of A Hetero Ring (e.g., Acetonide, Etc.) Patents (Class 514/174)
-
Publication number: 20120251594Abstract: Pharmaceutically engineered aerosols (e.g. submicrometer and nano-particles and droplets) containing a hygroscopic growth excipient or agent are employed to improve the delivery of respiratory aerosols to the lung. Inclusion of the hygroscopic agent results in near zero depositional loss in the nose-mouth-throat regions and near 100% deposition of the aerosol in the lung. Targeting of the aerosol to specific lung depths is also possible. In addition, methods and apparatuses for delivering aerosols to the lung are provided. The aerosol is delivered to one nostril of a patient while a relatively high humidity gaseous carrier is delivered to the other nostril, resulting in post-nasopharyngeal growth of the aerosol to a size that promotes deposition in the lung.Type: ApplicationFiled: November 9, 2010Publication date: October 4, 2012Inventors: Philip Worth Longest, Michael Hindle
-
Patent number: 8273725Abstract: A pharmaceutical composition comprising in admixture a hyaluronic acid related component (HARC) and a pharmaceutically effective amount of triamcinolone hexacetonide (TAH). The composition is stable in an accelerated shelf life test in which the composition is heated to 80° C. for 24 hours.Type: GrantFiled: September 10, 2009Date of Patent: September 25, 2012Assignee: Genzyme CorporationInventors: Grace Chang, Elizabeth Voschin, Li-Ping Yu, Eugene Skrabut
-
Patent number: 8268240Abstract: The present invention provides methods of manufacturing a sterile ciclesonide-containing aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.Type: GrantFiled: August 19, 2009Date of Patent: September 18, 2012Assignee: Nycomed GmbHInventors: Yoshihisa Nishibe, Atsuhiro Nagano, Kazuya Takanashi, Yasuhide Uejima
-
Patent number: 8258124Abstract: The subject matter of this application relates to the combination of ciclesonide or an epimer thereof with R,R-formoterol or a salt, or a hydrate of a salt thereof.Type: GrantFiled: December 20, 2010Date of Patent: September 4, 2012Assignee: Nycomed GmbHInventors: Christian Weimar, Klaus Dietzel, Helgert Müller, Degenhard Marx
-
Publication number: 20120220559Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.Type: ApplicationFiled: May 2, 2012Publication date: August 30, 2012Applicant: COSMO TECHNOLOGIES LIMITEDInventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
-
Publication number: 20120219599Abstract: The present disclosure describes an implant for improving bone growth including an osteoconductive scaffold and an osteoinductive small molecule. The osteoconductive scaffold can further include a polymeric binder. The implant can also include an osteogenic material to provide a viable cell population to assist the bone repair and remodeling. Also disclosed is a system for forming an implant for improving bone growth, as well as methods for forming the implant according to the disclosure, in addition to methods of therapeutic use of the implant.Type: ApplicationFiled: February 24, 2012Publication date: August 30, 2012Inventors: Meredith Hans Moore, Doug Buechter, Melissa Brown, Lisa Hughes, Stephen Hornsby
-
Patent number: 8252308Abstract: The present invention provides a substantially clear gel designed to reduce itching discomfort when applied to the vulvar tissue. The gel includes at least one anesthetic, protectant, emulsifier, and pH modifier, such as a base. The gel has a pH adapted to vulvar use and may be applied to the vulvar tissues.Type: GrantFiled: January 27, 2005Date of Patent: August 28, 2012Assignee: C.B. Fleet Company Inc.Inventors: Nelson Ayala, Michael L. Caswell
-
Publication number: 20120214776Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.Type: ApplicationFiled: August 31, 2010Publication date: August 23, 2012Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LTD.Inventors: Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
-
Publication number: 20120213850Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.Type: ApplicationFiled: May 2, 2012Publication date: August 23, 2012Applicant: COSMO TECHNOLOGIES LIMITEDInventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
-
Publication number: 20120213772Abstract: The invention provides for a method for identifying a biomarker in a fecal sample of a subject in need of such identification comprising: determining whether a fecal sample collected from a subject comprises a biomarker.Type: ApplicationFiled: January 13, 2012Publication date: August 23, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Janet R. Jansson, Benjamin Willing, Phillippe Schmitt-Kopplin, Agnes Fekete, Marianna Lucio
-
Publication number: 20120207682Abstract: The invention provides methods of treating macular edema in a patient that include determining whether the patient has been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time. If the patient has been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time, the method of treatment includes administering a therapeutically effective amount of an AED to the patient. If the patient has not been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time, the method of treatment optionally includes treating the patient with a therapy other than an AED. The invention further provides methods of treating macular edema in a patient using methods of and devices for administering an AED.Type: ApplicationFiled: February 13, 2012Publication date: August 16, 2012Applicant: pSivida US, Inc.Inventor: Paul Ashton
-
Patent number: 8242099Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.Type: GrantFiled: October 12, 2011Date of Patent: August 14, 2012Assignee: Allergan, Inc.Inventors: Vernon G. Wong, Mae W. L. Hu
-
Publication number: 20120201747Abstract: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.Type: ApplicationFiled: February 2, 2012Publication date: August 9, 2012Applicant: POP TEST CORTISOL LLCInventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
-
Publication number: 20120201800Abstract: The present invention includes methods and devices for providing sustained in-vivo release of an active agent to a subject. In some aspects, such release may be achieved by reacting an active agent in-vivo with a depot forming agent in order to form a sustained release active agent depot inside the subject. The depot can then release the active agent over a sustained period of time.Type: ApplicationFiled: August 8, 2011Publication date: August 9, 2012Inventors: John W. Higuchi, S. Kevin Li, William I. Higuchi, Matthew S. Hastings
-
Patent number: 8232304Abstract: A topical composition and the method using the composition, which contains an antifungal agent and a low potency anti-inflammatory steroid which is safe and effective such as desonide or its derivative. The low potency steroid agent does not cause side effects such as skin atrophy, striae and hypopigmentation. In a representative example, the low potency anti-inflammatory steroid has the following structure: wherein R1, R2, R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, and phenyl groups; R1 and R2 taken together can be C3-C10 cycloalkyl; and R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, phenyl, C7-C10 phenylalkyl, carboxylate, sulfonyl, phosphoryl, and phosphonyl groups. The composition can be formulated in a dosage form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution.Type: GrantFiled: October 23, 2003Date of Patent: July 31, 2012Assignee: G & R Pharmaceuticals, LLCInventors: Jay A. Goldstein, Michael Rothman, Whe-Yong Lo
-
Publication number: 20120183610Abstract: The present invention relates to improved glucocorticoid therapy and to treatment or prevention of a number of disorders that are due to a diminished or disrupted endogenous glucocorticoid secretory pattern. The invention is based on the findings that producing a specific serum Cortisol time profile that mimics the circadian rhythm of Cortisol of a healthy subject in a subject suffering from a diminished or disrupted glucocorticoid secretory pattern gives benefits with respect to reduction of side-effects.Type: ApplicationFiled: April 7, 2010Publication date: July 19, 2012Inventors: Hans Lennernäs, Jörgen Johnsson, Thomas Hedner, Gudmundur Johannsson, Stanko Skrtic
-
Publication number: 20120157373Abstract: Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents.Type: ApplicationFiled: February 29, 2012Publication date: June 21, 2012Applicant: MEDTRONIC, INC.Inventors: Paul Hsien-Fu Wu, Catherine E. Taylor, Linnus Cheruiyot, Jianwei Li, Terese A. Bartlett, Matt Bergan
-
Publication number: 20120142652Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.Type: ApplicationFiled: February 6, 2012Publication date: June 7, 2012Inventors: Patrick M. Hughes, Orest Olejnik, Scott M. Whitcup, James A. Burke
-
Publication number: 20120141587Abstract: Compositions, methods and kits for treatment or prevention of post operative organ or tissue inflammation are provided. The compositions contain an effective amount for local delivery, of an anti-inflammatory agent, alone or in combination with other pharmacologic agents, embedded within a polymeric matrix or gel. The polymeric matrix or gel may be a formed from natural or synthetic precursor components. The compositions are applied locally to an organ or tissue for the treatment or prevention of post inflammation resulting from surgical intervention.Type: ApplicationFiled: August 25, 2010Publication date: June 7, 2012Inventors: Dale Yoo, Sean Parick Whalen, Jonathan Langberg
-
Patent number: 8193172Abstract: The present invention relates to a method for the treatment of a patient suffering from major depressive disorder by administering to the patient an effective amount of a glucocorticoid receptor antagonist and to methods for establishing the optimal treatment regimen.Type: GrantFiled: November 18, 2002Date of Patent: June 5, 2012Assignee: Pop Test Cortisol LLCInventors: Cornelis C. Sennef, Bernardus Wijnand Mathys Marie Peeters
-
Publication number: 20120132204Abstract: An inhaler includes a first body member and a second body member fit closely together to form an inhaler body, and an outlet. The first body member has a medicament chamber containing a unit dose of powdered medicament. A seal such as a foil strip seals the medicament chamber and extends outwardly of the inhaler body. In use, one end of the seal can be grasped by a user and withdrawn, fully or partially, from the inhaler body, to release the powdered medicament from the medicament chamber. The second body member includes a medicament collection well in which the medicament is collected upon its release from the medicament chamber. The medicament collection well forms part of an airway connecting into the outlet. In use, air can be drawn by inhalation at the outlet to entrain the powder medicament in the collection well for inhalation by a user.Type: ApplicationFiled: February 9, 2012Publication date: May 31, 2012Applicant: INNOVATA BIOMED LIMITEDInventors: Samuel W. Lucking, Glen P. Martyn
-
Publication number: 20120135046Abstract: A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area.Type: ApplicationFiled: September 20, 2011Publication date: May 31, 2012Applicant: MAP PHARMACEUTICALS, INC.Inventors: Libo WU, Wiwik WATANABE, Jian ZHANG
-
Publication number: 20120129824Abstract: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.Type: ApplicationFiled: November 2, 2011Publication date: May 24, 2012Inventors: Arturo Angel, Gordon Dow
-
Patent number: 8182824Abstract: The present invention provides a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the concentration of ciclesonide after autoclaving is 95% or more compared to that before autoclaving.Type: GrantFiled: July 2, 2003Date of Patent: May 22, 2012Assignee: NYCOMED GmbHInventors: Yoshihisa Nishibe, Atsuhiro Nagano, Kazuya Takanashi, Yasuhide Uejima
-
Patent number: 8178519Abstract: The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.Type: GrantFiled: November 16, 2005Date of Patent: May 15, 2012Assignee: Norton Healthcare LimitedInventors: John Miller, Paul Ronald, Adrian Ashley, Paul Lamb, Donald MacDonald, Martin Oliver, Matthew Pollard
-
Publication number: 20120115829Abstract: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.Type: ApplicationFiled: January 17, 2012Publication date: May 10, 2012Applicant: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Ruma Sarkar
-
Publication number: 20120107406Abstract: A dry powder suitable for inhalation n a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period of time that is less than 60 minutes.Type: ApplicationFiled: October 27, 2011Publication date: May 3, 2012Applicant: Jagotec AGInventors: Rudi Mueller-Walz, Roland Steiner
-
Publication number: 20120093759Abstract: Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described.Type: ApplicationFiled: November 17, 2011Publication date: April 19, 2012Inventor: David J. Vachon
-
Publication number: 20120087957Abstract: Process for preparing sterile suspensions for inhalation comprising an active ingredient insoluble in water and wherein at least 80% of the particles of said active ingredient have a diameter between 3 and 5 ?m, comprising the following stages: dissolving the active ingredient in the minimum quantity of an alcoholic solvent, optionally in the presence of a polyol and adding at least one surfactant, filtering the solution obtained in the previous stage through a sterilizing filter, adding the solution from stage (b) to sterile water under sonication to directly obtain a suspension wherein the particles have a reduced diameter.Type: ApplicationFiled: December 21, 2011Publication date: April 12, 2012Applicant: CHIESI FARMACEUTICAL S.P.A.Inventors: Celestino RONCHI, Giancarlo CESCHEL
-
Publication number: 20120070469Abstract: Nanoparticulate assemblies of isolated ?-casein are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. The nanoparticulate assemblies can be freeze-dried and re-suspended prior to administration.Type: ApplicationFiled: August 18, 2011Publication date: March 22, 2012Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Yechezkel BARENHOLZ, Dganit Danino
-
Patent number: 8124597Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.Type: GrantFiled: August 22, 2008Date of Patent: February 28, 2012Assignees: The Hospital for Sick Children, McMaster UniversityInventors: Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
-
Publication number: 20120035146Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.Type: ApplicationFiled: October 12, 2011Publication date: February 9, 2012Inventors: Vernon G. Wong, Mae W. L. Hu
-
Publication number: 20120028944Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.Type: ApplicationFiled: January 27, 2011Publication date: February 2, 2012Applicant: OCULIS EHFInventors: Thorsteinn Loftsson, Einar Stefansson
-
Publication number: 20120021052Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.Type: ApplicationFiled: September 7, 2011Publication date: January 26, 2012Applicant: COSMO TECHNOLOGIES LIMITEDInventors: ROBERTO VILLA, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
-
Publication number: 20120021053Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.Type: ApplicationFiled: September 30, 2011Publication date: January 26, 2012Applicant: COSMO TECHNOLOGIES LIMITEDInventors: Roberto VILLA, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
-
Publication number: 20120016467Abstract: Disclosed is a sustained release system that includes a polymer and a prodrug having a solubility less than about 1 mg/ml dispersed in the polymer. Advantageously, the polymer is permeable to the prodrug and may be non-release rate limiting with respect to the rate of release of the prodrug from the polymer. This permits improved drug delivery within a body in the vicinity of a surgery via sustained release rate kinetics over a prolonged period of time, while not requiring complicated manufacturing processes.Type: ApplicationFiled: July 19, 2011Publication date: January 19, 2012Applicant: pSivida Inc.Inventors: Jianbing Chen, Paul Ashton, Thomas J. Smith
-
Publication number: 20110301129Abstract: Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.Type: ApplicationFiled: June 3, 2011Publication date: December 8, 2011Applicant: DEPOMED, INC.Inventors: BRET BERNER, JENNY LOUIE-HELM
-
Publication number: 20110294766Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: February 27, 2009Publication date: December 1, 2011Applicant: AstraZeneca ABInventors: Frank Burkamp, Tesfaledet Mussie, Paul Andersson, Inga-Britt Andersson, Sumita Bhatacharyya, Håkan Bladh, Svetlana Ivanova, Matti Lepistö
-
Publication number: 20110294717Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.Type: ApplicationFiled: December 15, 2010Publication date: December 1, 2011Inventors: Mir M. Ali, Abhimanyu Sabnis, David Dewitt, Greg Troiano, James Wright, Maria Figueiredo, Michael Figa, Tina Van Geen Hoven, Young-Ho Song, Jason Auer, Tarikh C. Campbell
-
Publication number: 20110294769Abstract: The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability.Type: ApplicationFiled: August 10, 2011Publication date: December 1, 2011Applicants: FERRER INTERNACIONAL S.A., NICOX S.A.Inventors: Francesca BENEDINI, Ennio Ongini, Antonio Guglietta, Daniel Palop, Marta Princep
-
Publication number: 20110288060Abstract: This invention provides an oscillating baffled reactor apparatus for preparing crystalline particles of at least one substance comprising: a reactor vessel; means for supplying a first flowing stream; means for oscillating fluid within the reactor vessel; a plurality of baffles; source of ultrasonic radiation; and means for collecting said particles.Type: ApplicationFiled: January 5, 2010Publication date: November 24, 2011Applicant: PROSONIX LIMITEDInventors: Graham Ruecroft, John Burns
-
Publication number: 20110281834Abstract: The present invention provides pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of a corticosteroid to the skin.Type: ApplicationFiled: November 10, 2009Publication date: November 17, 2011Inventors: Phillip M. Friden, Hyun Kim, Bireswar Chakraborty
-
Publication number: 20110269722Abstract: The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.Type: ApplicationFiled: December 23, 2010Publication date: November 3, 2011Inventor: Apparao Satyam
-
Publication number: 20110262368Abstract: The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the general structure formula (VII): wherein L, R1, R2, R3, R4, and R5 are selected independently of each other and as defined herein. Also provided are pharmaceutical compositions, methods of preparing, and methods of using such compounds in the treatment and prophylaxis of a wide range of immune, autoimmune, and inflammatory diseases and conditions. The novel compounds of the present invention possess useful pharmacological activity while having unexpectedly low systemic activity. Thus, the compounds of the invention represent a safer alternative to those known glucocorticoids which have poor side-effect profiles.Type: ApplicationFiled: December 18, 2008Publication date: October 27, 2011Applicant: Schering CorporationInventors: John C. Anthes, Kevin D. McCormick, John A. Hey, Robert G. Aslanian, Purakkattle J. Biju, Michael Y. Berlin, Daniel M. Solomon, Philippa H. Solomon, Hongwu Yang, Yeon-Hee Lim, Yoon Joo Lee, Rema Danielle Bitar
-
Publication number: 20110262543Abstract: Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared.Type: ApplicationFiled: April 21, 2011Publication date: October 27, 2011Applicant: Chiesi Farmaceutici S.p.A.Inventors: Daniela Cocconi, Rossella Musa
-
Publication number: 20110263492Abstract: A method for preparing a formulation containing nanoparticles of a compound is described. The method includes forming the compound into nanoparticles and then delivering the nanoparticles directly to a collection media. The collection media is a desired component of the formulation.Type: ApplicationFiled: October 19, 2010Publication date: October 27, 2011Inventors: Nahed M. Mohsen, Thomas A. Armer
-
Publication number: 20110238036Abstract: An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.Type: ApplicationFiled: December 22, 2010Publication date: September 29, 2011Applicant: pSivida US, Inc.Inventor: Paul Ashton
-
Publication number: 20110230455Abstract: An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively highType: ApplicationFiled: May 31, 2011Publication date: September 22, 2011Applicant: AVENTIS PHARMACEUTICALS INC.Inventor: Soo-Il KIM
-
Publication number: 20110223203Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.Type: ApplicationFiled: November 24, 2010Publication date: September 15, 2011Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
-
Publication number: 20110223216Abstract: The subject matter disclosed herein relates to compositions and methods for engineering porous particles for aerosol formulations for pulmonary drug delivery. Certain embodiments disclosed herein further relate to methods for stabilizing suspension-based formulations in hydrofluoroalkane propellants with nanoparticles.Type: ApplicationFiled: November 17, 2009Publication date: September 15, 2011Applicant: WAYNE STATE UNIVERSITYInventors: Sandro R.P. Da Rocha, Libo Wu